Dapagliflozin Propanediol — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

5 Recruiting

3 Completed trials

9 Sponsors

14 Countries

Phase II

Phase III/IV

Phase IV

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase III/IV: 3 Phase IV: 4

Indications tested

Chronic kidney disease 2 Overweight 1 Obesity 1

Sponsors using this IMP

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 2 Novo Nordisk A/S 2 Andrea Di Marco 1 Assistance Publique Hopitaux De Paris 1 Gentofte Hospital 1 Karolinska University Hospital 1 Steno Diabetes Center Copenhagen 1 University Of Oxford 1 Uppsala University 1

All trials

11 total

Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the t… Not authorised

2025-523374-17-01 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Fun… Pending

2024-517040-65-02 Phase I/II 1 country Gentofte Hospital
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the t… Pending

2025-523374-17-03 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi… Recruiting

2025-521780-12-00 Phase III/IV 1 country Andrea Di Marco
CKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease Recruiting

2023-507449-27-01 Phase IV 5 countries Steno Diabetes Center Copenhagen
RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR… Recruiting

2024-513719-28-00 Phase III/IV 1 country Karolinska University Hospital
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting

2023-508798-94-00 Phase III 1 country Assistance Publique Hopitaux De Paris
SGLT2 inhibitor or metformin as standard treatment in early type 2 diabetes (SMARTEST) Recruiting

2024-516228-33-00 Phase IV 1 country Uppsala University
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Phase II 9 countries Novo Nordisk A/S
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Phase II 6 countries Novo Nordisk A/S
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart… Ended

2022-502409-14-00 Phase III/IV 1 country University Of Porto

Showing 1–11 of 11 trials

← All drugs A–Z